158 related articles for article (PubMed ID: 21654897)
41. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
Nixon DR
J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.
Konstas AG; Kozobolis VP; Katsimpris IE; Boboridis K; Koukoula S; Jenkins JN; Stewart WC
Ophthalmology; 2007 Apr; 114(4):653-7. PubMed ID: 17197028
[TBL] [Abstract][Full Text] [Related]
43. Rebound tonometry in conscious, conditioned mice avoids the acute and profound effects of anesthesia on intraocular pressure.
Johnson TV; Fan S; Toris CB
J Ocul Pharmacol Ther; 2008 Apr; 24(2):175-85. PubMed ID: 18355131
[TBL] [Abstract][Full Text] [Related]
44. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
45. Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
Hayashi K; Yoshida M; Sato T; Manabe SI
Am J Ophthalmol; 2019 Sep; 205():91-98. PubMed ID: 30902694
[TBL] [Abstract][Full Text] [Related]
46. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost.
Konstas AG; Voudouragkaki IC; Boboridis KG; Haidich AB; Paschalinou E; Giannopoulos T; Dragoumis ND; Makridis AK; Kahook MY
Adv Ther; 2014 Jun; 31(6):592-603. PubMed ID: 24919410
[TBL] [Abstract][Full Text] [Related]
47. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
48. Intraocular pressure lowering efficacy of travoprost.
Przydryga JT; Egloff C;
Eur J Ophthalmol; 2004; 14(5):416-22. PubMed ID: 15506604
[TBL] [Abstract][Full Text] [Related]
49. Effect of acute increases of intraocular pressure on corneal pachymetry in eyes treated with travoprost: an animal study.
Bolívar G; Teus M; Arranz-Marquez E
Curr Eye Res; 2011 Nov; 36(11):1014-9. PubMed ID: 21942300
[TBL] [Abstract][Full Text] [Related]
50. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
Coleman AL; Lerner F; Bernstein P; Whitcup SM
Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
[TBL] [Abstract][Full Text] [Related]
51. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma.
Suh MH; Park KH; Kim DM
Jpn J Ophthalmol; 2009 Jan; 53(1):18-23. PubMed ID: 19184304
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.
Orengo-Nania S; Landry T; Von Tress M; Silver LH; Weiner A; Davis AA;
Am J Ophthalmol; 2001 Dec; 132(6):860-8. PubMed ID: 11730649
[TBL] [Abstract][Full Text] [Related]
53. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
54. Diurnal Variation and Effects of Dilation and Sedation on Intraocular Pressure in Infant Rhesus Monkeys.
Beach KM; Hung LF; Lou L; Ostrin LA
Curr Eye Res; 2023 Mar; 48(3):289-296. PubMed ID: 36357337
[TBL] [Abstract][Full Text] [Related]
55. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
56. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
58. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
59. Effects of travoprost 0.004% compared with latanoprost 0.005% on the intraocular pressure of normal dogs.
Carvalho AB; Laus JL; Costa VP; Barros PS; Silveira PR
Vet Ophthalmol; 2006; 9(2):121-5. PubMed ID: 16497237
[TBL] [Abstract][Full Text] [Related]
60. Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.
Nordmann JP; Berdeaux G
Clin Ther; 2007 Aug; 29(8):1751-60; discussion 1750. PubMed ID: 17919556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
